These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34463425)

  • 1. Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
    Dejgaard TF; von Scholten BJ; Christiansen E; Kreiner FF; Bardtrum L; von Herrath M; Mathieu C; Madsbad S;
    Diabetes Obes Metab; 2021 Dec; 23(12):2752-2762. PubMed ID: 34463425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
    Pieber TR; Deller S; Korsatko S; Jensen L; Christiansen E; Madsen J; Heller SR
    Diabetes Obes Metab; 2015 Aug; 17(8):742-50. PubMed ID: 25855340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
    Frandsen CS; Dejgaard TF; Andersen HU; Holst JJ; Hartmann B; Thorsteinsson B; Madsbad S
    Diabetes Obes Metab; 2017 Jun; 19(6):773-782. PubMed ID: 27868372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.
    Dejgaard TF; Schmidt S; Frandsen CS; Vistisen D; Madsbad S; Andersen HU; Nørgaard K
    Diabetes Obes Metab; 2020 Apr; 22(4):492-500. PubMed ID: 31696598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus.
    Mader JK; Jensen L; Ingwersen SH; Christiansen E; Heller S; Pieber TR
    Clin Pharmacokinet; 2016 Nov; 55(11):1457-1463. PubMed ID: 27282158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis.
    Dimitrios P; Michael D; Vasilios K; Konstantinos S; Konstantinos I; Ioanna Z; Konstantinos P; Spyridon B; Asterios K
    Curr Diabetes Rev; 2020; 16(4):313-326. PubMed ID: 31203802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.
    Lane W; Weinrib S; Rappaport J; Hale C
    Diabetes Obes Metab; 2014 Sep; 16(9):827-32. PubMed ID: 24589127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
    Meneghini L; Doshi A; Gouet D; Vilsbøll T; Begtrup K; Őrsy P; Ranthe MF; Lingvay I
    Diabet Med; 2020 Feb; 37(2):267-276. PubMed ID: 31705547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.
    Blonde L; Fainberg U; Kaltoft MS; Mosenzon O; Ramesh C; Rea R
    Diabetes Obes Metab; 2021 Oct; 23(10):2234-2241. PubMed ID: 34132018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is insulin the preferred treatment for HbA1c >9%?
    Bloomgarden Z
    J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.
    Tack CJ; Jacob S; Desouza C; Bain SC; Buse JB; Nauck MA; Petrie JR; Poulter NR; Pratley RE; Stegmann HVBK; Bosch-Traberg H; Startseva E; Zinman B;
    Diabetes Obes Metab; 2019 Nov; 21(11):2450-2458. PubMed ID: 31282028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.
    Billings LK; Agner BFR; Altuntas Y; Grøn R; Halladin N; Klonoff DC; Tentolouris N; Jódar E
    J Diabetes Sci Technol; 2021 May; 15(3):636-645. PubMed ID: 32107930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 receptor agonist, in African-American people with Type 2 diabetes: a meta-analysis of sub-population data from seven phase III trials.
    Shomali ME; Ørsted DD; Cannon AJ
    Diabet Med; 2017 Feb; 34(2):197-203. PubMed ID: 27412701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.
    Dejgaard TF; Knop FK; Tarnow L; Frandsen CS; Hansen TS; Almdal T; Holst JJ; Madsbad S; Andersen HU
    BMJ Open; 2015 Apr; 5(4):e007791. PubMed ID: 25838513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.
    Kuhadiya ND; Dhindsa S; Ghanim H; Mehta A; Makdissi A; Batra M; Sandhu S; Hejna J; Green K; Bellini N; Yang M; Chaudhuri A; Dandona P
    Diabetes Care; 2016 Jun; 39(6):1027-35. PubMed ID: 27208343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.
    Rodbard HW; Buse JB; Woo V; Vilsbøll T; Langbakke IH; Kvist K; Gough SC
    Diabetes Obes Metab; 2016 Jan; 18(1):40-8. PubMed ID: 26343931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study.
    Abreu M; Tumyan A; Elhassan A; Peicher K; Papacostea O; Dimachkie P; Siddiqui MS; Pop LM; Gunasekaran U; Meneghini LF; Adams-Huet B; Li X; Lingvay I
    Diabetes Obes Metab; 2019 Sep; 21(9):2133-2141. PubMed ID: 31144435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.